{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T07:55:05Z","timestamp":1772697305628,"version":"3.50.1"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To investigate the impact of proprotein convertase subtilisin kexin type-9 inhibitor (PCSK9i) on patients with metabolic dysfunction-associated fatty liver disease (MAFLD) combined with type 2 diabetes mellitus (T2DM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This retrospective study reviewed the clinical data of 60 inpatients with MAFLD combined with T2DM from the electronic medical record (EMR) system. According to the medical records, all patients were categorized into the Control group (\n                      <jats:italic>n<\/jats:italic>\n                      = 30, atorvastatin 20 mg QN) and the PCSK9i group (\n                      <jats:italic>n<\/jats:italic>\n                      = 30, evolocumab injection 140 mg Q2W in addition to atorvastatin). Body mass index (BMI), glycemic control, hepatic fibrosis and steatosis surrogate indicators such as aspartate aminotransferase to platelet ratio index (APRI), fibrosis-4 index (FIB-4), fatty liver index (FLI) and controlled attenuation parameter (CAP), and lipid profiles, including total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), were analyzed at baseline and the 12-week follow-up in both groups. Multivariable regression analyses for changes in hepatic fibrosis and steatosis surrogate indicators were performed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      At the 12-week follow-up, both groups exhibited significant reductions in lipid levels, with the PCSK9i group demonstrating greater decreases in TC (48.65 vs. 23.32%) and LDL-C (25.84 vs. 21.09%) compared to the Control group (\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.05). Meanwhile, the PCSK9i group exhibited significantly greater reductions in CAP (22.41 vs. 15.60%) and FLI (27.72 vs. 13.77%) in unadjusted analyses (both\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.05). Multivariable regression analyses demonstrated the superior improvement in CAP and FLI observed with PCSK9-i is independent of concomitant sodium-glucose co-transporter 2 inhibitor (SGLT-2i) therapy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>PCSK9i effectively reduced hepatic steatosis surrogate scores (FLI, CAP) and lipid levels (TC, LDL-C) in patients with MAFLD combined with T2DM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1756998","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T06:55:56Z","timestamp":1772693756000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["PCSK9 inhibitors improve lipid profile and hepatic steatosis surrogate indicators in patients with MAFLD and type 2 diabetes"],"prefix":"10.3389","volume":"13","author":[{"given":"Qingna","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, NHC Key Lab of Hormones and Development and Tianjin Key Lab of Metabolic Diseases, Tianjin Medical University Chu Hsien-I Memorial Hospital & Institute of Endocrinology","place":["Tianjin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoxia","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Ultrasound, NHC Key Lab of Hormones and Development and Tianjin Key Lab of Metabolic Diseases, Tianjin Medical University Chu Hsien-I Memorial Hospital & Institute of Endocrinology","place":["Tianjin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunzhao","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, NHC Key Lab of Hormones and Development and Tianjin Key Lab of Metabolic Diseases, Tianjin Medical University Chu Hsien-I Memorial Hospital & Institute of Endocrinology","place":["Tianjin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Congqing","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Integrated Traditional Chinese and Western Medicine, NHC Key Lab of Hormones and Development and Tianjin Key Lab of Metabolic Diseases, Tianjin Medical University Chu Hsien-I Memorial Hospital & Institute of Endocrinology","place":["Tianjin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuena","family":"Bi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Beichen Hospital of Nankai University","place":["Tianjin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology"},{"key":"B2","doi-asserted-by":"publisher","first-page":"20420188221142452","DOI":"10.1177\/20420188221142452","article-title":"Emerging pharmacological treatment options for MAFLD","volume":"13","author":"Rojas","year":"2022","journal-title":"Ther Adv Endocrinol Metab."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1291501","DOI":"10.3389\/fmed.2024.1291501","article-title":"Metabolic-associated fatty liver disease: a selective review of pathogenesis, diagnostic approaches, and therapeutic strategies","volume":"11","author":"Habibullah","year":"2024","journal-title":"Front Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.tem.2021.04.008","article-title":"Links between metabolic syndrome and metabolic dysfunction-associated fatty liver disease","volume":"32","author":"Lim","year":"2021","journal-title":"Trends Endocrinol Metab."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.3390\/ijms22052350","article-title":"Treatments for NAFLD: state of art","volume":"22","author":"Mantovani","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1206642","DOI":"10.3389\/fendo.2023.1206642","article-title":"Editorial: metabolic associated fatty liver disease: clinical perspectives from pathogenesis to diagnosis and treatment","volume":"14","author":"Huang","year":"2023","journal-title":"Front Endocrinol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"148","DOI":"10.5114\/pg.2023.126054","article-title":"Effects of PCSK9 inhibitors on metabolic-associated fatty liver disease: a short review","volume":"18","author":"Jakielska","year":"2023","journal-title":"Przeglad gastroenterologiczny."},{"key":"B8","doi-asserted-by":"publisher","first-page":"3654","DOI":"10.2174\/1381612824666181010123127","article-title":"The role of PCSK9 in the pathogenesis of non-alcoholic fatty liver disease and the effect of PCSK9 inhibitors","volume":"24","author":"Theocharidou","year":"2018","journal-title":"Curr Pharm Des."},{"key":"B9","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/s42003-025-07656-1","article-title":"Targeting fatty acid synthase reduces aortic atherosclerosis and inflammation","volume":"8","author":"Meade","year":"2025","journal-title":"Commun Biol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2008.06.010","article-title":"Molecular basis of PCSK9 function","volume":"203","author":"Lambert","year":"2009","journal-title":"Atherosclerosis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1161\/ATVBAHA.115.306032","article-title":"PCSK9 Induces CD36 degradation and affects long-chain fatty acid uptake and triglyceride metabolism in adipocytes and in mouse liver","volume":"35","author":"Demers","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1080\/13543776.2024.2340569","article-title":"PCSK9 inhibitors: a patent review 2018-2023","volume":"34","author":"Fassi","year":"2024","journal-title":"Expert Opin Ther Pat."},{"key":"B13","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s12933-022-01542-4","article-title":"PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a Bayesian network meta-analysis","volume":"21","author":"Wang","year":"2022","journal-title":"Cardiovasc Diabetol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"101550","DOI":"10.1016\/j.cpcardiol.2022.101550","article-title":"Qualitative and quantitative effects of PCSK9 inhibitors in familial hypercholesterolemia: a synthetic review","volume":"48","author":"Shakir","year":"2023","journal-title":"Curr Probl Cardiol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1177\/2047487317724342","article-title":"PCSK9 deficiency results in increased ectopic fat accumulation in experimental models and in humans","volume":"24","author":"Baragetti","year":"2017","journal-title":"Eur J Prev Cardiol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.jhepr.2019.10.009","article-title":"Pcsk9 knockout exacerbates diet-induced non-alcoholic steatohepatitis, fibrosis and liver injury in mice","volume":"1","author":"Lebeau","year":"2019","journal-title":"JHEP Rep."},{"key":"B17","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/978-1-0716-1924-7_27","article-title":"Atherosclerosis induced by adeno-associated virus encoding gain-of-function PCSK9","volume":"2419","author":"Bj\u00f8rklund","year":"2022","journal-title":"Methods Mol Biol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.4254\/wjh.v12.i12.1258","article-title":"Effects of proprotein convertase subtilisin\/kexin type-9 inhibitors on fatty liver","volume":"12","author":"Shafiq","year":"2020","journal-title":"World J Hepatol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology."},{"key":"B20","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.2337\/dc23-S003","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes care"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1161521","DOI":"10.3389\/fendo.2023.1161521","article-title":"Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments","volume":"14","author":"Ruze","year":"2023","journal-title":"Front Endocrinol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1002\/hep.32728","article-title":"The associations between modifiable risk factors and nonalcoholic fatty liver disease: a comprehensive Mendelian randomization study","volume":"77","author":"Xie","year":"2023","journal-title":"Hepatology."},{"key":"B23","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S2213-8587(22)00003-1","article-title":"A global view of the interplay between non-alcoholic fatty liver disease and diabetes","volume":"10","author":"Stefan","year":"2022","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"632","DOI":"10.2337\/dc15-1876","article-title":"Metabolic impact of nonalcoholic steatohepatitis in obese patients with type 2 diabetes","volume":"39","author":"Lomonaco","year":"2016","journal-title":"Diabetes Care."},{"key":"B25","doi-asserted-by":"publisher","first-page":"Cd011748","DOI":"10.1002\/14651858.CD011748.pub3","article-title":"PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease","volume":"10","author":"Schmidt","year":"2020","journal-title":"Cochrane Database Syst Rev."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1016\/j.ajpath.2021.04.016","article-title":"Proprotein convertase subtilisin\/kexin type 9: a view beyond the canonical cholesterol-lowering impact","volume":"191","author":"Macchi","year":"2021","journal-title":"Am J Pathol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.atherosclerosis.2017.04.023","article-title":"New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4\/NF-\u03baB pathway","volume":"262","author":"Tang","year":"2017","journal-title":"Atherosclerosis."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.3390\/ijms241411396","article-title":"Smad3 mediates diabetic dyslipidemia and fatty liver in db\/db mice by targeting PPAR\u03b4","volume":"24","author":"He","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1007\/s10753-023-01865-8","article-title":"Anti-PCSK9 treatment attenuates liver fibrosis via inhibiting hypoxia-induced autophagy in hepatocytes","volume":"46","author":"Ning","year":"2023","journal-title":"Inflammation."},{"key":"B30","doi-asserted-by":"publisher","first-page":"16","DOI":"10.14744\/hf.2024.2024.0024","article-title":"Performance of non-invasive fibrosis markers in biopsy-proven liver disorders","volume":"6","author":"Danis","year":"2025","journal-title":"Hepatol Forum"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e66257","DOI":"10.7759\/cureus.66257","article-title":"Incidence of non-alcoholic fatty liver disease (NAFLD)\/non-alcoholic steatohepatitis (NASH) in the female population of North Karnataka: a cross-sectional study","volume":"16","author":"Desai","year":"2024","journal-title":"Cureus."},{"key":"B32","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13293-024-00617-z","article-title":"Fatty liver index (FLI) is the best score to predict MASLD with 50% lower cut-off value in women than in men","volume":"15","author":"Crudele","year":"2024","journal-title":"Biol Sex Differ."},{"key":"B33","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3390\/nu10020157","article-title":"Liver fat scores moderately reflect interventional changes in liver fat content by a low-fat diet but not by a low-carb diet","volume":"10","author":"Kabisch","year":"2018","journal-title":"Nutrients"},{"key":"B34","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.numecd.2020.11.009","article-title":"Analysis of steatosis biomarkers and inflammatory profile after adding on PCSK9 inhibitor treatment in familial hypercholesterolemia subjects with nonalcoholic fatty liver disease: a single lipid center real-world experience","volume":"31","author":"Scicali","year":"2021","journal-title":"Nutr Metab Cardiovasc Dis."},{"key":"B35","doi-asserted-by":"publisher","first-page":"609135","DOI":"10.3389\/fendo.2020.609135","article-title":"Sodium-glucose co-transporter 2 inhibitors for non-alcoholic fatty liver disease in Asian patients with type 2 diabetes: a meta-analysis","volume":"11","author":"Wong","year":"2020","journal-title":"Front Endocrinol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"609110","DOI":"10.3389\/fendo.2021.609110","article-title":"Glucagon-like peptide-1 receptor agonists for non-alcoholic fatty liver disease in type 2 diabetes: a meta-analysis","volume":"12","author":"Wong","year":"2021","journal-title":"Front Endocrinol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1756998\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T06:55:57Z","timestamp":1772693757000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1756998\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,5]]},"references-count":36,"alternative-id":["10.3389\/fmed.2026.1756998"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1756998","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,5]]},"article-number":"1756998"}}